Showing results (111-120 of 123) with videos related to
Sort By:
Pageof 13
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2021
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) StudyJin Lu, Weijun Fu, Wei Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 2022
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, et al.Blood|September 21, 2022
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trialsBruno Paiva, Irene Manrique, Meletios A Dimopoulos, et al.BMC Medicine|April 5, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm studyLugui Qiu, Zhongjun Xia, Chengcheng Fu, et al.British Journal of Haematology|May 16, 2023
Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre studyLinghui Zhou, Weijun Fu, Shenghao Wu, et al.Cancer|December 11, 2024
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1Zhen Cai, Zhongjun Xia, Ai-Li He, et al.Clinical Lymphoma, Myeloma & Leukemia|April 6, 2023
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS StudyWeijun Fu, Soo-Mee Bang, Honghui Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2023
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical TrialTingyu Wang, Xiuhua Sun, Lihua Qiu, et al.Cancer|January 4, 2026
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohortThomas G Martin, María-Victoria Mateos, Jun Ho Yi, et al.BMJ (Clinical Research Ed.)|January 28, 2026
Reliability of urological telesurgery compared with local surgery: multicentre randomised controlled trialYe Wang, Dan Xia, Wanhai Xu, et al.Pageof 13